# Anti-CD20 Antibodies for Treatment of SLE-PAH

> **NCT05828147** · PHASE4 · UNKNOWN · sponsor: **Chinese SLE Treatment And Research Group** · enrollment: 50 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT05828147
- **Lead sponsor:** Chinese SLE Treatment And Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-25
- **Primary completion:** 2025-03
- **Final completion:** 2026-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05828147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05828147, "Anti-CD20 Antibodies for Treatment of SLE-PAH". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05828147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*